Viadur

Endometriosis, Iron Deficiency Anemia, Iron replacement therapy + 6 more
Treatment
20 Active Studies for Viadur

What is Viadur

LeuprolideThe Generic name of this drug
Treatment SummaryLeuprolide is a medication used to reduce the production of sex hormones by mimicking the effects of an important hormone in the body called gonadotropin-releasing hormone (GnRH). It is approved to treat advanced prostate cancer, endometriosis, and precocious puberty. It is usually administered as an injection every six months. Leuprolide was first approved in 1985 and is marketed under the brand name Lupron™ by Abbvie Endocrine Inc.
Lupronis the brand name
image of different drug pills on a surface
Viadur Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lupron
Leuprolide
1986
57

Effectiveness

How Viadur Affects PatientsLeuprolide is a medication that affects the body's hormones, such as testosterone and estradiol. In women, it can worsen symptoms like pain or bleeding, and long-term use can lead to a decrease in bone mineral density. It can also cause vision issues and an increased risk of cardiovascular disease. In men, it can cause tumour flare, hyperglycemia, diabetes, and other cardiovascular issues. In children with central precocious puberty, it can cause convulsions and mental health issues like irritability and anger.
How Viadur works in the bodyLeuprolide affects the body by affecting the hypothalamic-pituitary-gonadal (HPG) axis. It does this by binding to receptors on the anterior pituitary gland, prompting the production of hormones like testosterone, dihydrotestosterone, estrone, and estradiol. Initially, this causes a spike in hormones, which can lead to side effects. After two to four weeks, the hormones decrease, leading to a therapeutic benefit. Once treatment is stopped, these effects are reversed.

When to interrupt dosage

The advised dosage of Viadur is based on the determined condition, such as Anger Management Therapy, Central Precocious Puberty (CPP) and Uterine Fibroids. The quantity of dosage differs, contingent upon the method of delivery (e.g. Intramuscular or Intramuscular; Topical) specified in the table underneath.
Condition
Dosage
Administration
Iron replacement therapy
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
confirmed by clinical features
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Palliative Treatment
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Endometriosis
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Iron Deficiency Anemia
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
symptom recurrence
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Central Precocious Puberty (CPP)
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Advanced Prostate Cancer
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Uterine Fibroids
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Warnings

Viadur has six contra-indications and should not be used simultaneously with the ailments listed in the table below.Viadur Contraindications
Condition
Risk Level
Notes
Vaginal Hemorrhage
Do Not Combine
Pregnant Women
Do Not Combine
Metrorrhagia
Do Not Combine
presence or history of breast cancer
Do Not Combine
Neoplasms, Hepatic
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Leuprolide may interact with Pulse Frequency
There are 20 known major drug interactions with Viadur.
Common Viadur Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.
Viadur Toxicity & Overdose RiskLeuprolide is generally safe with low toxicity, and mild side effects. Even after two years of taking doses as high as 20 mg/day, prostate cancer patients did not experience any additional adverse effects compared to those taking 1 mg/day.
image of a doctor in a lab doing drug, clinical research

Viadur Novel Uses: Which Conditions Have a Clinical Trial Featuring Viadur?

144 active clinical trials are presently being conducted to assess the efficacy of Viadur in alleviating symptoms of recurrence, Uterine Fibroids and Iron Deficiency Anemia.
Condition
Clinical Trials
Trial Phases
Iron Deficiency Anemia
114 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Phase 3, Phase 4, Early Phase 1
Endometriosis
32 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1
Uterine Fibroids
11 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Early Phase 1, Phase 4
Palliative Treatment
0 Actively Recruiting
confirmed by clinical features
0 Actively Recruiting
Central Precocious Puberty (CPP)
1 Actively Recruiting
Phase 3
symptom recurrence
0 Actively Recruiting
Advanced Prostate Cancer
7 Actively Recruiting
Early Phase 1, Phase 1, Not Applicable, Phase 2
Iron replacement therapy
0 Actively Recruiting

Viadur Reviews: What are patients saying about Viadur?

5Patient Review
1/16/2009
Viadur for Advanced Form of Prostate Cancer
I experienced hot flashes, sweating, some breast enlargement, no sex drive whatsoever, and a decrease in testicle size.
4.7Patient Review
11/14/2008
Viadur for Advanced Form of Prostate Cancer
4.3Patient Review
11/29/2008
Viadur for Advanced Form of Prostate Cancer
It's been tough to sleep since my surgery. Sometimes sleeping pills help, but it's a temporary solution at best. I had my prostate removed as well as five lymph nodes. Two of them showed cancer, but so far all of the tests are coming back negative.
4Patient Review
4/27/2008
Viadur for Advanced Form of Prostate Cancer
3Patient Review
3/16/2010
Viadur for Osteoporosis
This treatment is great. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about viadur

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Viadur

Have you considered Viadur clinical trials? We made a collection of clinical trials featuring Viadur, we think they might fit your search criteria.
Have you considered Viadur clinical trials? We made a collection of clinical trials featuring Viadur, we think they might fit your search criteria.
Have you considered Viadur clinical trials? We made a collection of clinical trials featuring Viadur, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top